-transparent.png){kind=logo}
To investigate the effect of conjugated equine estrogens on the coagulability in menopausal women, blood samples were drawn from 69 menopausal females--35 receiving estrogens and 34 receiving no replacement therapy. Using tests for antithrombin and heparin-antithrombin activities, 14.7% of the control patients were found to be hypercoagulable. This is a 289% increase in the incidence of hypercoagulability in the group treated with estrogens. The particular relevance of this finding to menopausal women and the importance of the use of the coagulation profile in managing such patients is discussed.
Related Publications
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
June 1982,
American journal of obstetrics and gynecology,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
August 2019,
Journal of the Endocrine Society,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
January 1993,
Investigacion clinica,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
November 1970,
Das Medizinische Laboratorium,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
February 2016,
American family physician,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
January 2001,
Journal of the American Medical Directors Association,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
January 1995,
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
December 1966,
The Journal of investigative dermatology,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
January 1976,
Revista chilena de obstetricia y ginecologia,
J J Stangel, and
I Innerfield, and
J V Reyniak, and
M L Stone
January 2012,
International journal of women's health,
